WCN26-3872 Effects of Incretin-based Therapies on Kidney Outcomes in Obese Patients without Diabetes

Read full text Summarise with VIRAT
Authors: Takayuki Yamada, Shota Obata, Shunichiro Tsukamoto, Yuki Kawai, Kazushi Uneda, Tetsuro Aoi, Kenta Okada, Kazuki Nakayama, Yuki Obayashi, Yasuto Sunahara, Tomoharu Ida
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Obesity is a global health burden and an important risk factor for cardiovascular and kidney disease. Obesity-related kidney injury develops through hyperfiltration, oxidative stress, and inflammation. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists induce weight loss and improve renal outcomes in type 2 diabetes; however, their effects in obese individuals without diabetes remain unclear.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Diabetes Treatment and Management Adipokines Inflammation and Metabolic Diseases

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105734–105734
Publication date
25 March 2026
Language
EN